A Big Boost for Amgen
Amgen (AMGN) found relief on word that the Food and Drug Administration voted against setting dosing limits on the company's blockbuster anemia drug Epogen for kidney disease patients. Shares of Amgen rose 4.7% to $56.46 on heavy trading volume on the Nasdaq on Sept. 12.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.